Wayne B. Weisman

Founder at SCP Vitalife Partners

Wayne B. Weisman

Wayne B. Weisman

Founder at SCP Vitalife Partners

Overview
Career Highlights

SCP Vitalife Partners

RelSci Relationships

924

Number of Boards

32

Birthday

1956

Age

64

Contact Data
Trying to get in touch with Wayne B. Weisman? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Wayne B. Weisman likely has professional access to. A relationship does not necessarily indicate a personal connection.

President & Chief Executive Officer at Recro Pharma, Inc.

Relationship likelihood: Strong

Co-Founder at Gesu School

Relationship likelihood: Strong

Founder at SCP Vitalife Partners

Relationship likelihood: Strong

Partner at SCP Private Equity Partners

Relationship likelihood: Strong

Venture Partner at SCP Private Equity Partners

Relationship likelihood: Strong

Managing Partner at SCP Vitalife Partners

Relationship likelihood: Strong

Chief Financial Officer at SCP Private Equity Partners

Relationship likelihood: Strong

President & Chief Executive Officer at Echo 360, Inc.

Relationship likelihood: Strong

Venture Partner at SCP Private Equity Partners

Relationship likelihood: Strong

Chief Administrative Officer & General Counsel at SCP Private Equity Partners

Relationship likelihood: Strong

Paths to Wayne B. Weisman
Potential Connections via
Relationship Science
You
Wayne B. Weisman
Founder at SCP Vitalife Partners
Career History
Managing Member
2007 - Current

SCP Vitalife Management Co. LLC is an American private company located in Wayne, PA. The firm provides investment advice.

Founder
2000 - Current

SCP Vitalife Partners invests mainly in Israeli medical technology companies. The firm focuses on early- to mid-stage life science technologies and services with emphasis on therapeutic medical devices. Specifically, SCP's investment focus includes: (1) medical devices for therapeutic uses (2) novel diagnostic methods especially imaging (3) biomaterials (4) specialty pharmaceuticals and drug delivery and (5) healthcare services. The firm looks for companies with a market opportunity that is large enough to allow for growth over several years. SCP is particularly interested in companies with products or services that are positioned to capitalize on major structural changes within their target markets. The firm also targets companies with intellectual property that provides them with strong barriers to competitive entry. Initial investments range from $3 million to $7 million with the typical total investment ranging from $7 million to $15 million over the life of the investment.

Partner
1996 - Current

SCP Partners is a principal investment firm specializing in early stage companies with exceptional technology or other proprietary advantages that are poised to capitalize on major market trends; expansion stage companies that are largely past product or technology development risk and can demonstrate some level of actual market validation; and later stage, middle market, and buyout opportunities that are attractively priced and offer upside growth potential through strategy modification and management rejuvenation. The firm seeks to invest in information and communications technology which includes network hardware and software, wireless communications, distributed computing and interoperable web-based services, rich media creation and distribution infrastructure, and Internet infrastructure; life sciences which includes medical devices for therapeutic uses, novel diagnostics and imaging, specialty pharmaceuticals, and drug delivery; services including financial services, health care services, information technology services, and medical services; and defense and security which includes surveillance and monitoring, flexible, rapid deployment communications technologies for military and emergency situations, software for operationally intensive environments, and data archiving, search, and retrieval. It primarily invests in the United States and can also consider a limited number of investments in foreign countries.

Boards & Committees
Director
Current
Director
Current
Director
Current
Chairman, Board of Trustees
Current
Political Donations
$500
2012
$2,500
2011
Investments
Details Hidden

Auxilium Pharmaceuticals LLC develops and markets pharmaceutical products. It specializes in men's healthcare area and has product portfolio and pipeline in orthopedics, dermatology and other therapeutic areas. The firm products include edex, Osbon, ErecAid, STENDRA, TESTOPEL, XIAFLEX and Testim. The company was founded by Gerri A. Henwood and Jane Holmes Hollingsworth in 1999 and is headquartered in Chesterbrook, PA.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Wayne B. Weisman. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Wayne B. Weisman's profile does not indicate a business or promotional relationship of any kind between RelSci and Wayne B. Weisman.